Research Analysts Issue Forecasts for Opthea FY2025 Earnings

Opthea Limited (NASDAQ:OPT) – Equities research analysts at HC Wainwright lifted their FY2025 EPS estimates for shares of Opthea in a research note issued on Tuesday, March 25th. HC Wainwright analyst M. Caufield now expects that the company will earn ($1.44) per share for the year, up from their previous estimate of ($1.60). HC Wainwright currently has a “Neutral” rating and a $2.00 target price on the stock. The consensus estimate for Opthea’s current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Opthea’s FY2026 earnings at ($0.96) EPS, FY2027 earnings at ($0.56) EPS, FY2028 earnings at ($0.24) EPS and FY2029 earnings at $0.24 EPS.

OPT has been the topic of several other reports. Leerink Partnrs downgraded Opthea from a “strong-buy” rating to a “hold” rating in a report on Monday. Leerink Partners lowered Opthea from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $12.00 to $1.00 in a research note on Tuesday. Canaccord Genuity Group upgraded Opthea to a “strong-buy” rating in a research note on Tuesday, December 17th. Jefferies Financial Group reiterated an “underperform” rating and set a $1.00 price target (down previously from $8.00) on shares of Opthea in a research report on Tuesday. Finally, Oppenheimer lowered shares of Opthea from an “outperform” rating to a “market perform” rating in a report on Monday. One analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Opthea presently has a consensus rating of “Hold” and an average price target of $1.33.

Opthea Stock Up 7.2 %

Shares of Opthea stock opened at $3.41 on Thursday. The firm’s 50-day moving average price is $4.41 and its two-hundred day moving average price is $4.06. Opthea has a 1-year low of $1.79 and a 1-year high of $6.30.

Institutional Trading of Opthea

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Citadel Advisors LLC acquired a new stake in Opthea during the 4th quarter worth $79,000. Hsbc Holdings PLC acquired a new position in shares of Opthea in the 4th quarter valued at $556,000. OLD Mission Capital LLC bought a new position in shares of Opthea in the 4th quarter worth $42,000. ABC Arbitrage SA acquired a new stake in shares of Opthea during the fourth quarter worth $40,000. Finally, Twin Lakes Capital Management LLC bought a new stake in Opthea in the third quarter valued at about $81,000. 55.95% of the stock is owned by institutional investors.

About Opthea

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.